Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-mp689 Total loading time: 0 Render date: 2024-04-20T14:50:19.493Z Has data issue: false hasContentIssue false

Chapter 7 - Oral and infusion levodopa therapy in the management of Parkinson's disease

from Section I - The Pharmacological Basis for Parkinson's Disease Treatment

Published online by Cambridge University Press:  05 March 2016

By
M. Angela Cenci-Nilsson  and
Per Odin
Edited by
Néstor Gálvez-Jiménez ,
Hubert H. Fernandez ,
Alberto J. Espay  and
Susan H. Fox
Néstor Gálvez-Jiménez
Affiliation:
Cleveland Clinic, Florida
Hubert H. Fernandez
Affiliation:
Cleveland Clinic, Ohio
Alberto J. Espay
Affiliation:
University of Cincinnati
Susan H. Fox
Affiliation:
Toronto Western Hospital
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Parkinson's Disease
Current and Future Therapeutics and Clinical Trials
 , pp. 63 - 75
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Fearnley, JM, Lees, AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114 : 2283–301.Google Scholar
Brooks, DJ, Frey, KA, Marek, KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 2003; 184 (Suppl. 1): S68–79.CrossRefGoogle ScholarPubMed
Chaudhuri, KR, Odin, P, Antonini, A, Martinez-Martin, P. Parkinson's disease: the non-motor issues. Parkinsonism Relat Disord 2011; 17: 717–23.Google Scholar
Cenci, MA, Ohlin, KE, Odin, P. Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease. CNS Neurol Disord Drug Targets 2011; 10: 670–84.Google Scholar
Salat, D, Tolosa, E. Levodopa in the treatment of Parkinson's disease: current status and new developments. J Parkinsons Dis 2013; 3: 255–69.Google Scholar
Heremans, E, Nieuwboer, A, Vercruysse, S. Freezing of gait in Parkinson's disease: where are we now? Curr Neurol Neurosci Rep 2013; 13: 350.CrossRefGoogle ScholarPubMed
Carlsson, A, Lindqvist, M, Magnusson, T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957; 180: 1200.CrossRefGoogle ScholarPubMed
Hornykiewicz, O. Die Topische Lokalisation und das Verhalten von Noradrenalin und Dopamin in der Substantia Nigra des normalen und Parkinsonkranken Menschen. Wien Klin Wochenschr 1963; 75: 309–12.Google Scholar
Birkmayer, W, Hornykiewicz, O. Der L-Dioxyphenylalanin (=DOPA – Effekt bei der Parkinson-akinase. Wien Klin Wschr 1961; 73: 787–8.Google Scholar
Barbeau, A, Sourkes, TL, Murphy, GF. Les catécholamines dans la maladie de Parkinson. In: de Ajuriaguerra, J, ed. Monoamines et Systéme Nerveaux Central. Geneva: Georg & Cie SA; 1962; 247–62.Google Scholar
Cotzias, G, Van Woert, M, Schiffer, L. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374–9.Google Scholar
Calne, DB, Reid, JL, Vakil, SD et al. Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. BMJ 1971; 3: 729–32.Google Scholar
Cenci, MA, Lundblad, M. Post- versus presynaptic plasticity in l-DOPA-induced dyskinesia. J Neurochem 2006; 99: 381–92.Google Scholar
Nutt, JG, Holford, NH. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996; 39: 561–73.Google Scholar
Nyholm, D, Lennernas, H, Gomes-Trolin, C, Aquilonius, SM. Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. Clin Neuropharmacol 2002; 25: 89–96.Google Scholar
Contin, M, Martinelli, P. Pharmacokinetics of levodopa. J Neurol 2010; 257 (Suppl. 2): S253–61.Google Scholar
Nyholm, D, Stepien, V. Levodopa fractionation in Parkinson's disease. J Parkinsons Dis 2014; 4: 89–96.Google Scholar
Fasano, A, Bove, F, Gabrielli, M, et al. The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2013; 28: 1241–9.Google Scholar
Chapuis, S, Ouchchane, L, Metz, O, Gerbaud, L, Durif, F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005; 20: 224–30.Google Scholar
Fabbrini, G, Brotchie, JM, Grandas, F, Nomoto, M, Goetz, CG. Levodopa-induced dyskinesias. Mov Disord 2007; 22: 1379–89; quiz 523.CrossRefGoogle ScholarPubMed
Stacy, M, Bowron, A, Guttman, M, et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005; 20: 726–33.Google Scholar
Fahn, S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs later l-DOPA. Arch Neurol 1999; 56: 529–35.Google Scholar
Fahn, S. A new look at levodopa based on the ELLDOPA study. J Neural Transm Suppl 2006: 419–26.Google Scholar
Stocchi, F, Rascol, O, Kieburtz, K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010; 68: 18–27.Google Scholar
Castro-Garcia, A. [Psychiatric complications of L-dopa: physiopathology and treatment]. Rev Neurol. 1997; 25 (Suppl. 2): S157–62.Google Scholar
Weintraub, D, Koester, J, Potenza, MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589–95.CrossRefGoogle ScholarPubMed
O'Sullivan, SS, Evans, AH, Lees, AJ. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 2009; 23: 157–70.Google Scholar
Spencer, AH, Rickards, H, Fasano, A, Cavanna, AE. The prevalence and clinical characteristics of punding in Parkinson's disease. Mov Disord 2011; 26: 578–86.Google Scholar
Storch, A, Schneider, CB, Wolz, M, et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013; 80: 800–9.Google Scholar
Rossi, P, Colosimo, C, Moro, E, Tonali, P, Albanese, A. Acute challenge with apomorphine and levodopa in Parkinsonism. Eur Neurol. 2000; 43: 95–101.Google Scholar
Cedarbaum, JM, Kutt, H, McDowell, FH. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). Neurology 1989; 39 (Suppl. 2): 38–44; discussion 59.Google Scholar
MacMahon, DG, Sachdev, D, Boddie, HG, et al. A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53: 220–3.Google Scholar
Gauthier, S, Amyot, D. Sustained release antiparkinson agents: controlled release levodopa. Can J Neurol Sci 1992; 19 (Suppl.): 153–5.Google Scholar
Sage, JI, Mark, MH. Pharmacokinetics of continuous-release carbidopa/levodopa. Clin Neuropharmacol 1994; 17 (Suppl. 2): S1–6.Google Scholar
Block, G, Liss, C, Reines, S, Irr, J, Nibbelink, D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997; 37: 23–7.Google Scholar
Wolters, EC, Tesselaar, HJ. International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease. J Neurol 1996; 243: 235–40.Google Scholar
Jankovic, J, Schwartz, K, Vander Linden, C. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Mov Disord 1989; 4: 303–9.CrossRefGoogle ScholarPubMed
Koller, WC, Hutton, JT, Tolosa, E, Capilldeo, R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 1999; 53: 1012–9.CrossRefGoogle ScholarPubMed
Baas, H, Zehrden, F, Selzer, R, et al. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. Clin Pharmacokinet 2001; 40: 383–93.Google Scholar
Kuoppamaki, M, Korpela, K, Marttila, R, et al. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol 2009; 65: 443–55.Google Scholar
Adler, CH, Singer, C, O'Brien, C, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol 1998; 55: 1089–95.Google Scholar
Deane, KH, Spieker, S, Clarke, CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2004; CD004554.Google Scholar
Kurth, MC, Adler, CH, Hilaire, MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997; 48: 81–7.Google Scholar
Rocha, JF, Santos, A, Falcao, A, et al. Effect of moderate liver impairment on the pharmacokinetics of opicapone. Eur J Clin Pharmacol 2014; 70: 279–86.CrossRefGoogle ScholarPubMed
Rascol, O, Brooks, DJ, Melamed, E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365: 947–54.Google Scholar
Olanow, CW, Rascol, O, Hauser, R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268–78.Google Scholar
Adler, CH, Sethi, KD, Hauser, RA, et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997; 49: 393–9.Google Scholar
Shannon, KM, Bennett, JP Jr, Friedman, JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 1997; 49: 724–8.Google Scholar
Fahn, S, Oakes, D, Shoulson, I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498–508.Google Scholar
Rinne, UK, Bracco, F, Chouza, C, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology 1997; 48: 363–8.Google Scholar
Oertel, WH, Wolters, E, Sampaio, C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord 2006; 21: 343–53.Google Scholar
Rascol, O, Brooks, DJ, Korczyn, AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484–91.Google Scholar
Butzer, JF, Silver, DE, Sahs, AL. Amantadine in Parkinson's disease. A double-blind, placebo-controlled, crossover study with long-term follow-up. Neurology 1975; 25: 603–6.Google Scholar
Fox, SH, Katzenschlager, R, Lim, SY, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011; 26 (Suppl. 3): S2–41.Google Scholar
Hauser, RA, Ellenbogen, AL, Metman, LV, et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Mov Disord 2011; 26: 2246–52.Google Scholar
Hauser, RA, Hsu, A, Kell, S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 2013; 12: 346–56.Google Scholar
Hauser, RA. Future treatments for Parkinson's disease: surfing the PD pipeline. Int J Neurosci. 2011; 121 (Suppl. 2): 53–62.CrossRefGoogle ScholarPubMed
LeWitt, PA, Huff, FJ, Hauser, RA, et al. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. Mov Disord 2014; 29: 75–82.CrossRefGoogle ScholarPubMed
Stocchi, F, Zappia, M, Dall'Armi, V, et al. Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease. Mov Disord 2010; 25: 1881–7.Google Scholar
Nyholm, D, Ehrnebo, M, Lewander, T, et al. Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers. Acta Neurol Scand 2013; 127: 124–32.Google Scholar
Shoulson, I, Glaubiger, GA, Chase, TN. On–off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975; 25: 1144–8.Google Scholar
Quinn, N, Marsden, CD, Parkes, JD. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. Lancet 1982; 320: 412–5.Google Scholar
Kurlan, R, Rubin, AJ, Miller, C, et al. Duodenal delivery of levodopa for on–off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986; 20: 262–5.Google Scholar
Nyholm, D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Rev Neurother 2006; 6: 1403–11.CrossRefGoogle ScholarPubMed
Fernandez, HH, Odin, P. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease. Curr Med Res Opin. 2011; 27: 907–19.Google Scholar
Olanow, CW, Kieburtz, K, Odin, P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014; 13: 141–9.Google Scholar
Fernandez, HH, Vanagunas, A, Odin, P, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. Parkinsonism Relat Disord 2013; 19: 339–45.Google Scholar
Honig, H, Antonini, A, Martinez-Martin, P, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009; 24: 1468–74.Google Scholar
Busk, K, Nyholm, D. Long-term 24-h levodopa/carbidopa gel infusion in Parkinson's disease. Parkinsonism Relat Disord 2012; 18: 1000–1.Google Scholar
Seppi, K, Weintraub, D, Coelho, M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011; 26 (Suppl. 3): S42–80.Google Scholar
Ferreira, JJ, Katzenschlager, R, Bloem, BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol 2013; 20: 5–15.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×